Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

Extrahepatic biliary tract cancer (EBTC) in most cases is diagnosed at an unresectable stage of disease. Standard-of-care systemic palliative treatment consists of systemic anti-tumor therapy with or without immune-checkpoint-inhibitor (ICI). Nonetheless, overall survival remains limited at about 12.8 months. Moreover, severe adverse events can occur leading to treatment discontinuation increasing the risk of tumor progression and poor prognosis. Biliary obstruction is one of the most relevant factors for survival limiting eligibility and timing/dosing of chemo-(immuno)therapy. Endoscopic biliary stenting is standard to relieve jaundice, but tumor ingrowth can limit the rate and duration of success. Radiofrequency ablation (RFA) results from thermal damage created by a high-frequency alternating current released from an electrode into tissue. RFA has become a standard treatment modality in numerous indications, including the treatment of Barrett's oesophagus-related dysplasia and hepatocellular carcinoma. Intraductal biliary radiofrequency ablation (bRFA) is a relatively new method of inducing tumor necrosis via thermal energy. bRFA has been applied in patients suffering unresectable EBTC within randomized-controlled trials indicating improved stent patency as well as overall survival and progression-free survival.

The primary objective of the study is to provide evidence for the general tolerability of bRFA in patients with unresectable extrahepatic biliary tract cholangiocarcinoma undergoing systemic anti-tumor therapy with or without ICI. It is hypothesized that bRFA is generally safe and well tolerated by patients. Primary endpoint of the study is any grade 3 or 4 adverse events leading to chemo-immune checkpoint inhibitor-therapy discontinuation up to six months after enrolment.

Eligible patients will be registered in the study database and randomized in 1:2 ratio to either the standard group (systemic anti-tumor therapy with or without ICI with endoscopic biliary stenting) or the experimental bRFA group (systemic anti-tumor therapy with or without ICI with endoscopic biliary stenting + bRFA).

Systemic anti-tumor therapy with or without ICI with endoscopic biliary stenting are standard of care applied commonly in both the control and the experimental group:

Endoscopic retrograde cholangiography (ERC) procedure stenting are applied at baseline and as clinically indicated. E.g., CICI cycles (Gemcitabin d1 & d8, Cisplatin d1 & d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.

bRFA will be applied only to the experimental group, it is standardized as for generator settings and protocol adapting to tumor morphology using the probe at baseline, 6 and 12 weeks after study start.

Inclusion criteria

• Male or female ≥18 years old.
• Histologically or cytologically confirmed diagnosis of previously untreated and unresectable*, locally advanced and/or metastatic extrahepatic biliary tract cholangiocarcinoma with obstructive jaundice (increased serum level of total bilirubin).
• ECOG performance status 0 to 2.
• Adequate bone marrow function: Neutrophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L.
• Adequate renal function in case of cisplatin administration: Estimated Glomerular Filtration Rate (eGFR) ≥60mL/min/1.73m2.
• Willing and able to provide written informed consent.
• Planned initiation of any standard-of-care systemic anti-proliferative therapy against ETB.

*The reason for inoperability needs to be documented and categorized as follows:

• Wish of patient.
• Locally advanced or vascular invasion = surgically not removable.
• Remnant liver is not sufficient.
• Anatomic contraindications.
• Distant metastasis.
• Severe comorbidities.
• Other reasons. Exclusion criteria

<!-- -->

• Solely intrahepatic cholangiocarcinoma or mixed type liver tumors (cholangiocarcinoma with hepatocellular differentiation parts).
• Multiple hepatic metastases with significant blockage of one or more liver segments and/or less than 50% of liver parenchyma potentially drainable on pre-intervention imaging.
• In case of immune-checkpoint-inhibitor (ICI) administration, any autoimmune diseases including inflammatory disorders such as Crohn's disease, ulcerative colitis, Wegener granulomatosis, systemic lupus erythematosus, rheumatoid arthritis, Graves' disease.

Exceptions:

• Hypothyroidism following Hashimoto thyroiditis stable on hormone replacement.

• Patients with vitiligo.

• Any chronic skin disorders that do not require systemic treatment.
• Use of immunosuppressive medication within 3 weeks prior to ICI administration.

Exceptions:

• Topical or inhaled steroids.
• Systemic corticosteroids at physiologic doses not exceeding >10mg/d of prednisone or equivalent.
• Prior Self-Expandable Metal Stent (SEMS) placement in the biliary tree.
• Biliary obstruction of non-tumoral etiology.
• Platelets <100 x 109/L or International Normalized Ratio (INR) >1.5.
• Secondary tumor.

Exceptions:

• Tumor treated with curative intent without recurrence for more than 5 years.
• Non-melanoma skin cancer treated carcinoma in situ without evidence of disease.
• Pregnancy or lactation.
• Known or suspected non-compliance, drug, or alcohol abuse.
• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the candidate.
• Participation in another interventional study within 30 days prior to enrollment.
• Previous participation in the current study.
• Other diseases like Human Immunodeficiency Virus, Liver cirrhosis Child-Pugh B or C, cardiac pacemaker, history of organ transplantation or condition likely to significantly decrease life expectancy i.e., life expectancy is less than 3 months according to investigator judgement.